MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase II/III clinical trial for the treatment of breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; Enoblituzumab, a monoclonal antibody that targets B7-H3; and Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3. In addition, it is developing MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company's non-immuno-oncology clinical product candidates include MGD014, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ã CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; Janssen Biotech, Inc.; and Alligator Bioscience AB (publ). The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
IPO Year: 2013
Exchange: NASDAQ
Website: macrogenics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/1/2024 | Buy → Neutral | BTIG Research | |
7/31/2024 | $18.00 → $5.00 | Buy → Neutral | B. Riley Securities |
7/31/2024 | Buy → Neutral | Guggenheim | |
5/10/2024 | $24.00 → $8.00 | Outperform → Market Perform | BMO Capital Markets |
5/10/2024 | $29.00 → $7.00 | Buy → Hold | Stifel |
5/10/2024 | Buy → Hold | TD Cowen | |
4/26/2024 | $25.00 | Buy | B. Riley Securities |
4/9/2024 | Hold → Buy | TD Cowen | |
3/4/2024 | $12.00 → $24.00 | Buy | BTIG Research |
2/14/2024 | $12.00 → $14.00 | Buy → Neutral | H.C. Wainwright |
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of Dr. Margaret A. Liu and Meenu Chhabra Karson to its Board of Directors, effective January 3, 2023. Dr. Liu will serve as a member of MacroGenics' Science and Technology Committee and Ms. Karson will serve as a member of the Company's Audit Committee. Following the appointment of Dr. Liu and Ms. Karson, MacroGenics' Board will comprise ten directors, nine of whom are independent. "We are delighted to have both Margaret and Meenu join Ma
ROCKVILLE, MD, May 23, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the appointment of William Heiden to its Board of Directors, effective May 22, 2022. Mr. Heiden will serve as Chair of the board and a member of the Audit Committee. Following the appointment of Mr. Heiden, the Board will comprise eight directors, seven of whom are independent. Mr. Heiden is replacing Paulo F. Costa as Chair. Mr. Costa served in the Chair position until his term as director expired on May 19, 2022. "We are delighted to have Bill join Macr
ROCKVILLE, MD, Feb. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, President of CFO’Brien Consulting, LLC, to its Board of Directors. Federica O’Brien is a veteran executive with 25 years of financial and operational leadership in biopharmaceutical, medical device, and technology companies and currently serves on the Board of Directors of TELA Bio, Inc. where she also chairs the Audit Committee. Ms. O’Brien will be joining MacroGenics’ Audit Committee. "We are de
4 - MACROGENICS INC (0001125345) (Issuer)
Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:
Submission status for MACROGENICS INC's drug MARGENZA (ORIG-1) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 12/16/2020. Application Category: BLA, Application Number: 761150, Application Classification:
SC 13G - MACROGENICS INC (0001125345) (Subject)
SC 13G - MACROGENICS INC (0001125345) (Subject)
SC 13G/A - MACROGENICS INC (0001125345) (Subject)
SC 13G/A - MACROGENICS INC (0001125345) (Subject)
SC 13G - MACROGENICS INC (0001125345) (Subject)
SC 13G/A - MACROGENICS INC (0001125345) (Subject)
SC 13G/A - MACROGENICS INC (0001125345) (Subject)
SC 13G - MACROGENICS INC (0001125345) (Subject)
SC 13G/A - MACROGENICS INC (0001125345) (Subject)
SC 13G - MACROGENICS INC (0001125345) (Subject)
8-K - MACROGENICS INC (0001125345) (Filer)
10-Q - MACROGENICS INC (0001125345) (Filer)
8-K - MACROGENICS INC (0001125345) (Filer)
8-K - MACROGENICS INC (0001125345) (Filer)
8-K - MACROGENICS INC (0001125345) (Filer)
S-8 - MACROGENICS INC (0001125345) (Filer)
8-K - MACROGENICS INC (0001125345) (Filer)
8-K - MACROGENICS INC (0001125345) (Filer)
10-Q - MACROGENICS INC (0001125345) (Filer)
ARS - MACROGENICS INC (0001125345) (Filer)
4/A - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
4 - MACROGENICS INC (0001125345) (Issuer)
BTIG Research downgraded MacroGenics from Buy to Neutral
B. Riley Securities downgraded MacroGenics from Buy to Neutral and set a new price target of $5.00 from $18.00 previously
Guggenheim downgraded MacroGenics from Buy to Neutral
BMO Capital Markets downgraded MacroGenics from Outperform to Market Perform and set a new price target of $8.00 from $24.00 previously
Stifel downgraded MacroGenics from Buy to Hold and set a new price target of $7.00 from $29.00 previously
TD Cowen downgraded MacroGenics from Buy to Hold
B. Riley Securities initiated coverage of MacroGenics with a rating of Buy and set a new price target of $25.00
TD Cowen upgraded MacroGenics from Hold to Buy
BTIG Research reiterated coverage of MacroGenics with a rating of Buy and set a new price target of $24.00 from $12.00 previously
H.C. Wainwright downgraded MacroGenics from Buy to Neutral and set a new price target of $14.00 from $12.00 previously
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitam
Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte's advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-endConfirming cash runway guidance into 2026 ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2024. "We are pleased to have the opportunity to present
Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential risk/benefit to participants; most had received at least 8 cycles of vobra duoGiven embargoed TAMARACK data presentation at ESMO, Company plans to host an investor update call following E
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024. "We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a c
Presentation of preliminary data from TAMARACK Phase 2 study of vobra duo in mCRPC patients expected at ASCO 2024Initiation of Phase 1 study of MGC026, MacroGenics' first topoisomerase I inhibitor-based ADCPreclinical data on two topoisomerase I inhibitor-based ADC product candidates, MGC026 and MGC028, to be presented in posters at AACRConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., March 07, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progres
ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive
Completed enrollment of TAMARACK Phase 2 study of vobra duo ahead of scheduleInitiated LORIKEET Phase 2 study of lorigerlimab Submitted IND for MGC026, a topoisomerase inhibitor-based ADC Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2023. "Since mid-2022, we have received $335 million in non-dilutive capital from our coll
ROCKVILLE, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2023 after the market closes on Monday, November 6, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Monday, November 6, 2023, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receiv
Advancing enrollment of TAMARACK Phase 2 study in metastatic castration-resistant prostate cancer (mCRPC) under revised protocol Initiating lorigerlimab Phase 2 study in mCRPC patients Achieved $50 million milestone related to Sanofi's announcement of positive top-line data from TZIELD® (teplizumab-mzwv) type 1 diabetes study Conference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for t
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from Benzinga Pro. SAIC shares dipped 11% to $119.91 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Microbot Medical Inc. (NASDAQ:MBOT) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial. Bio-Pa
Analysts' ratings for Macrogenics (NASDAQ:MGNX) over the last quarter vary from bullish to bearish, as provided by 14 analysts. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 6 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 3 0 0 2M Ago 0 0 0 0 0 3M Ago 3 4 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Macrogenics, presenting an average target of $17.57, a high estimate of $29.00, and a low estimate of $4.00. Highlighting a 7.18% decrease, the current aver
BTIG analyst Kaveri Pohlman maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $24 to $9.
Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b
HC Wainwright & Co. analyst Robert Burns maintains Macrogenics (NASDAQ:MGNX) with a Neutral and lowers the price target from $16 to $4.
Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $25 to $14.
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARACK is being conducted in previously treated patients with metastatic castration-resistant prostate cancer (mCRPC). MacroGenics reported five deaths (fatal outcome) during the trial. It also reported over 50% rate of grade 3, or worse, adverse events in both dose cohorts (2 mg/kg and 2.7 mg/kg every four weeks). B Riley maintains the Buy rating on MacroGenics with a price target of $25. BMO Capital Markets downgraded MacroGenics from Outperform to Market Perform with a price target of $8 from $24 on lower conviction on the prostate cancer program.
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 100 points on Friday. The Dow traded up 0.24% to 39,482.36 while the NASDAQ fell 0.06% to 39,482.36. The S&P 500 also rose, gaining, 0.11% to 5,219.64 . Check This Out: Top 3 Industrials Stocks That May Collapse This Month Leading and Lagging SectorsFinancials shares rose by 0.4% on Friday. In trading on Friday, consumer discretionary shares fell by 0.7%. Top Headline The University of Michigan consumer sentiment declined to 67.4 in May versus 77.2 in the prior month, recording the weakest level in six months. However, markets were expecting a reading of 76. Equities Trading UP
JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price target from $22 to $16.
A worse-than-expected University of Michigan’s May consumer report halted stock gains on Friday, sparking worries about a potential decline in consumer health amid perceived rising price pressures. The report disclosed that both near-term and long-term inflation expectations have surged beyond projections this month, causing the broader consumer gauge to hit its lowest levels in six months. “If spending slows down and inflation increases, we'll get the opposite of the Goldilocks scenario that many were hoping for, and the Fed will be in an especially difficult position of choosing between accommodating a slowing economy and fighting increasing inflation expectations,” said Chris Zaccar
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced a poster presentation relating to Phase 2 data of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain from September 13-17, 2024. The following poster will be available on Sunday, September 15, 2024: TAMARACK: Randomized Phase 2 trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitam
Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte's advancement of ZYNYZ® (retifanlimab-dlwr) subsequent to quarter-endConfirming cash runway guidance into 2026 ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended June 30, 2024. "We are pleased to have the opportunity to present
Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential risk/benefit to participants; most had received at least 8 cycles of vobra duoGiven embargoed TAMARACK data presentation at ESMO, Company plans to host an investor update call following E
ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ® (retifanlimab-dlwr), following an agreement on July 24, 2024, pursuant to which certain milestones were deemed to have been met. ZYNYZ is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. ZYNYZ is a monoclonal anti
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month: Goldman Sachs 45th Annual Global Healthcare Conference (Miami Beach). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Thursday, June 13, 2024, at 10:00am ET. MacroGenics' management will also participate in one-on-one meetings. A webcast of the a
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 17, 2024 /PRNewswire/ -- USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage pancreatic cancer with 97% accuracy. This breakthrough is crucial, as Johns Hopkins Medicine reports that up to 10% of patients diagnosed early can become disease-free after treatment. The American Cancer Society estimates that around 66,440 people (34,530 men and 31,910 women) in the USA will be diagnosed with pancreatic cancer this year, with approximately 51,750 expected to succumb to the disease. Behind the scenes, biotech drug de
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month: The Citizens JMP Life Sciences Conference (New York). MacroGenics' President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 14, 2024, at 10:30 am ET. MacroGenics' management will also participate in one-on-one meetings.TD Cowen's 5th Annual Oncology Innovation Summit:
Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024. "We are very encouraged by the interim updated safety and preliminary efficacy data from the TAMARACK study of vobra duo in metastatic castration-
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024, at 4:30 pm ET. Conference Call Information To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a c
USA News Group Commentary Issued on behalf of BioVaxys Technology Corp. VANCOUVER, BC, May 1, 2024 /PRNewswire/ -- USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of cancer. A new report from the American Cancer Society projects that by 2050, the number of people diagnosed with cancer could rise by 77%. According to experts at last year's annual American Society of Clinical Oncology (ASCO) meeting, a little-known bacteria could be behind the rising rates of cancer in people under 40, along with pointing towards bad habits such as highly-processed diets and heavy alcohol use being potential catal